Brain Tumor Therapeutics Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

Market Trends and Insights

Late-stage pipeline expansion & accelerated FDA approvals

Regulatory speed continues to reshape the brain tumor therapeutics market. Vorasidenib’s 2024 approval for grade 2 IDH-mutant glioma doubled median progression-free survival versus placebo, validating biomarker-guided development paths^{[1]Drugs.com, “FDA Approves Vorasidenib for Low-Grade Glioma,” drugs.com}. Breakthrough therapy designations are compressing timelines, while investigational device exemptions now cover novel radiotherapy platforms such as Alpha DaRT’s radium-224 seeds for recurrent glioblastoma. Collective momentum shortens commercialization cycles and encourages multi-arm master trials that match molecular subsets with targeted agents.

Precision-medicine shift toward biomarker-guided therapies

Routine testing for IDH mutation, MGMT promoter methylation, and 1p/19q codeletion now guides regimen selection in leading centers. Liquid biopsy platforms provide real-time molecular readouts, allowing therapy switches before radiographic progression. Machine-learning algorithms integrating multi-omics profiles already predict immunotherapy responses with 90%+ accuracy, a capability that is refining eligibility criteria for checkpoint blockade.

Commercial roll-out of compact BNCT platforms

Japan has moved Boron Neutron Capture Therapy from experimental use to routine hospital service by installing compact accelerator-based neutron sources that replace the large research reactors used in earlier trials. More than 500 patients have already received the therapy, establishing a first real-world safety and efficacy record for the modality . Clinical programs are now extending beyond recurrent head-and-neck tumors to brain malignancies, helped by next-generation boron carriers such as peptide-conjugated compounds that accumulate more selectively in tumor tissue. Parallel Monte Carlo studies show that redesigned neutron generators can reach thermal-to-epithermal flux ratios that match IAEA treatment guidelines, a technical milestone that opens the door to broader disease applications and installation in regional cancer centers.

AI-assisted drug repurposing for orphan brain tumors

Machine-learning platforms that screen legacy compound libraries against multi-omics cancer datasets are compressing the discovery timeline for rare brain-tumor therapeutics from decades to only a few years. Pattern-recognition algorithms have already highlighted new uses for familiar molecules, including the repositioning of the anthelmintic mebendazole for glioblastoma, now protected in a recent patent filing. Model accuracy keeps improving as training sets combine genomic, transcriptomic and real-world treatment-outcome data, allowing developers to forecast drug response at the tumor-subtype level with high confidence. The approach is especially valuable for ultra-rare brain tumors whose small patient pools make conventional prospective trials impractical; AI-guided repurposing supplies clinically actionable candidates while minimizing both cost and time.

High cost of novel therapeutics & combination regimens

First-in-class cell and gene therapies often exceed USD 400,000 per course, while multi-agent combinations can add another USD 300,000 annually, straining payer budgets. Health systems now link reimbursement to real-world outcomes, creating coverage delays that limit early adoption in lower-income settings.

Blood–brain barrier limits small-molecule & biologic penetration

Only 2% of systemic molecules reach therapeutic concentrations in the brain, forcing reliance on high doses that raise systemic toxicity. Focused ultrasound, convection-enhanced delivery, and nanoparticle carriers are progressing, yet capital intensity and specialized training slow rollout beyond tertiary centers.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Brain Tumor Therapeutics Market Segment Analysis

Glioblastoma held 50.78% of brain tumor therapeutics market share in 2025 and is projected to grow at an 8.02% CAGR, sustaining the largest slice of the brain tumor therapeutics market size through 2031. High mortality, limited standard-of-care options, and the emergence of tumor-treating fields help maintain investor focus.

Continued device-drug pairings, peptide vaccines, and IDH-selective inhibitors illustrate capital concentration in this segment. Meningioma follows in value terms thanks to refined radiosurgery protocols, whereas pituitary tumors benefit from novel endocrine modulators that normalize hormone levels more predictably. Pediatric-leaning subtypes such as medulloblastoma and ependymoma now integrate risk-adapted radiotherapy with molecular diagnostics, improving five-year survival yet leaving relapsed disease an urgent research priority.

Immunotherapy commanded 32.10% revenue in 2025 and remains integral for high-mutational-burden tumors. Nonetheless, the precision-led approval wave now positions targeted small-molecule therapy as the fastest-growing category at an anticipated 8.10% CAGR, reflecting the brain tumor therapeutics market’s appetite for orally dosed, biomarker-matched agents.

Chemotherapy endures as adjuvant or salvage therapy, but dose-dense regimens face replacement as mutation-specific inhibitors gain reimbursement. Gene and cell therapies introduce curative potential yet confront scalability and cost. Meanwhile, radiotherapeutic adjuncts such as BNCT are expanding beyond head and neck indications, reinforcing multi-modal protocols.

The intravenous segment covered 55.62% of the brain tumor therapeutics market size in 2025 and should rise at an 7.90% CAGR through 2031. Clinicians rely on IV delivery for precise dose titration and real-time toxicity management in narrow therapeutic index drugs.

Oral targeted agents are scaling thanks to improved permeability and patient convenience, while intrathecal and intraventricular methods see niche use in leptomeningeal spread. Convection-enhanced delivery trials demonstrate 100-fold higher tumor concentrations versus systemic infusion, yet technical complexity confines it to referral centers.

Geography Analysis

North America Brain Tumor Therapeutics Market

North America maintained 39.88% market share in 2025 and enjoys unrivaled clinical-trial density, genomic testing adoption, and payer mechanisms that expedite new product uptake. The region’s large installed base of Gamma Knife and BNCT systems supports combination regimens, and philanthropic funding from the Biden Cancer Moonshot sustains translational research programs.

Europe Brain Tumor Therapeutics Market

Europe follows with steady contributions as EMA centralized approvals streamline access across member states, and public–private partnerships co-finance orphan-tumor projects. Germany, France, and Italy collectively host more than 120 ongoing brain tumor interventional studies, while pan-European registries supply real-world evidence to health technology assessment agencies.

APAC Brain Tumor Therapeutics Market

Asia-Pacific, the fastest-growing region at 8.12% CAGR, benefits from China’s regulatory modernization, where 60+ innovative drugs won clearance under accelerated pathways in 2024. Japan’s early BNCT adoption makes the country a regional referral hub, and Australian institutions leverage favorable ethics timelines to recruit international patients. Improving reimbursement frameworks in South Korea and Singapore further broaden patient access to leading-edge regimens.

Regulatory Landscape

Regulatory activity in brain tumor therapeutics is increasingly anchored in biomarker-defined labels and expedited pathways for high-unmet-need neuro-oncology indications. In the United States, the FDA approval of VORANIGO (vorasidenib) in August 2024 for grade 2 IDH1/IDH2-mutant glioma (including patients aged 12 years and older) reinforced mutation-guided development and supported standardized IDH testing in treatment pathways. The FDA has also used accelerated approval in ultra-rare brain tumors, including the August 2025 accelerated approval of Modeyso (dordaviprone) for recurrent H3 K27M-mutant diffuse midline glioma (patients aged 1 year and older), increasing the emphasis on confirmatory study commitments in commercialization planning.

In Europe, centralized review continues to shape access across member states through European Commission decisions supported by EMA assessments. The European Commission granted marketing authorization for Voranigo in September 2025, and in April 2026 granted conditional marketing authorization for Ojemda (tovorafenib) for pediatric low-grade glioma with specific BRAF alterations (from 6 months of age), illustrating how conditional authorization can enable earlier access on less comprehensive datasets for unmet medical need. Separately, proposed US legislative activity (S. 4739) directs the FDA Commissioner to issue guidance within one year of enactment aimed at minimizing exclusion of brain tumor patients from clinical trials for other indications, signaling a policy push toward broader trial access and eligibility modernization.

Market Opportunities and Future Outlook

The move toward genotype-defined subpopulations (IDH, H3 K27M, BRAF) is expanding commercial whitespace in earlier-line and pediatric settings where conventional chemotherapy and radiotherapy leave high relapse risk. Recent approvals such as VORANIGO (vorasidenib) for grade 2 IDH-mutant glioma (FDA, August 2024; European Commission authorization, September 2025) and Modeyso (dordaviprone) for recurrent H3 K27M-mutant diffuse midline glioma (FDA accelerated approval, August 2025) are increasing the routine use of molecular profiling in care pathways, which improves patient identification for targeted agents and supports development of adjacent companion diagnostic and testing services.

Glioblastoma continues to be a key opportunity area because standard regimens face blood-brain barrier limitations and immunotherapy resistance, driving demand for modalities with differentiated delivery or immune activation. In 2026, clinical and translational outputs highlighted multiple approaches under active investigation, including a July 2026 Journal of Clinical Oncology publication from IN8bio reporting Phase 1 data for INB-200 (DeltEx DRI) with progression-free survival of 16.1 months in repeat-dose glioblastoma patients versus 6.9 months for standard of care, alongside academic work on personalized neoantigen vaccine strategies and viral immunotherapy concepts. At the same time, the roll-out of BNCT infrastructure, particularly in Japan where more than 500 patients have received BNCT across real-world use, supports a longer-term pathway for radiotherapy adjunct uptake, while also emphasizing supply-chain constraints around radioisotopes that create openings for alternative production, logistics, and facility-side reliability solutions.